QQ客服 官方微博 反馈留言

	A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
	Han, Baohui; Li, Kai; Zhao, Yizhuo; Wang, Qiming; Zhang, Li; Shi, Jianhua; Wang, Zhehai; He, Jianxing; Shi, Yuankai; Cheng, Yin
刊名	JOURNAL OF THORACIC ONCOLOGY
	2017
卷号	12页码:S886-S887
关键词	NSCLC multi-targeted tyrosine kinase inhibitor Anlotinib
ISSN号	1556-0864
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2934327
专题	西安交通大学
推荐引用方式 GB/T 7714	Han, Baohui,Li, Kai,Zhao, Yizhuo,et al. A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)[J]. JOURNAL OF THORACIC ONCOLOGY,2017,12:S886-S887.
APA	Han, Baohui.,Li, Kai.,Zhao, Yizhuo.,Wang, Qiming.,Zhang, Li.,...&Wang, Hongbing.(2017).A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).JOURNAL OF THORACIC ONCOLOGY,12,S886-S887.
MLA	Han, Baohui,et al."A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)".JOURNAL OF THORACIC ONCOLOGY 12(2017):S886-S887.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。